Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Showcase


Channel Catalog


Channel Description:

Visit One News Page for Europe news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Europe news headlines.

older | 1 | .... | 1612 | 1613 | (Page 1614) | 1615 | 1616 | .... | 1652 | newer

    0 0

    TORONTO and PARIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Blockchain Foundry Inc. (“Blockchain Foundry” or “BCF”) (CSE:BCFN) (FWB:8BF) (OTC:BLFDF) and ARCHOS S.A. (“ARCHOS”) (EPA:JXR) are pleased to announce a strategic partnership covering blockchain hardware solutions and related software infrastructure (the “Agreement”). Pursuant to this partnership, BCF will become the exclusive North American distributor of the ARCHOS SAFE-T range of hardware cryptocurrency wallets and blockchain secured solutions.ARCHOS recently announced the development of the SAFE-T Touch, a ground-breaking innovation in the hardware wallet segment. The SAFE-T Touch offers a highly secure hardware wallet platform, embedding a trusted execution environment incorporating ProvenCore technology from Prove & Run S.A.S., a leading European software security firm. This focus on security, combined with a user-friendly mobile wallet interface, provides SAFE-T Touch users with the best of both worlds; a highly secure environment that is also convenient and easy to use.

    In consideration of the Agreement, BCF will grant ARCHOS 3.7 million common shares, representing approximately 5% of the outstanding shares of BCF. In addition, ARCHOS may be entitled to cash or share-based consideration of up to 10% of the gross revenue earned by BCF from ARCHOS products during 2019, based upon milestones including the appointment of BCF as ARCHOS’ preferred partner for blockchain development services. The Agreement and strategic partnership are arm’s length.

    “The BCF team has been developing products and services for blockchain since 2012. We are impressed by ARCHOS’ strategy and believe that its developments are setting new standards for hardware wallets, which are key to building a secure blockchain environment. BCF’s dedicated sales and marketing team will be actively targeting North American cryptocurrency asset holders and the cryptocurrency community in order to promote these innovative products and associated services platforms,” stated Dan Wasyluk, CEO of Blockchain Foundry.

    “This partnership is a key milestone for ARCHOS in the development of its Blockchain solutions. BCF’s track-record in Blockchain technology is impressive, including the creation of the Syscoin Platform and important B2B blockchain services developments like Blockmarket Desktop 3.0., a decentralized marketplace and cryptocurrency wallet. The team is highly efficient, user centric and motivated. They are recognized in the crypto community and are long term advocates of the benefits of hardware wallets and their vast use cases. Becoming a shareholder of BCF is important as it structures the partnership for the long term,” added Loic Poirier, CEO of ARCHOS.

    *About ARCHOS *

    ARCHOS, a pioneer in consumer electronics, continues to innovate and revolutionize the consumer electronics market. Among others, the French manufacturer was first with an HDD MP3 player in 2000, a multimedia player in 2003, Google Android powered tablets in 2009, a connected Smart Home in 2014 and PicoWAN, the first collaborative network dedicated to the IoT, in 2016. Today, ARCHOS designs and democratizes solutions with high innovation value in three segments: mobile solutions, AI, blockchains. With headquarters in France, offices in Europe and in Asia, ARCHOS is a strong pan-European player. ARCHOS is quoted on Compartment C of Eurolist, Euronext Paris, ISIN Code: FR0000182479.

    *About Blockchain Foundry *

    Blockchain Foundry Inc. develops and commercializes blockchain-based business solutions and provides consulting services to corporate clients seeking to incorporate blockchain technology into their businesses.

    Press contacts at ARCHOS:
    Bénédicte Ernoult – ernoult@archos.com - +33 (0)1 69 33 16 90
    Emmanuelle Bureau du Colombier – ebdc@archos.com - + 33 (0)6 09 47 23 49

    Press contacts at Blockchain Foundry:
    Christopher Marsh – cmarsh@blockchainfoundry.co - + 1 (647) 330-4572

    *Forward-Looking Information*

    Certain portions of this press release contain “forward-looking information” within the meaning of applicable Canadian securities legislation, which is also referred to as “forward-looking statements”, which may not be based on historical fact. Wherever possible, words such as “will”, “plans,” “expects,” “targets,” “continues”, “estimates,” “scheduled,” “anticipates,” “believes,” “intends,” “may,” “could,” “would” or might, and the negative of such expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved, have been used to identify forward looking information.

    Forward looking statements should not be read as guarantees of future events, future performance or results, and will not necessarily be accurate indicators of the times at, or by which, such events, performance or results will be achieved, if achieved at all. Readers should not place undue reliance on such forward-looking statements, as they reflect management’s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BCF are inherently subject to significant business, economic, regulatory, competitive, political and social uncertainties and contingencies. Many factors could cause BCF’s actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.

    Although BCF has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: unanticipated sales results, failure to meet milestones in a timely manner; changes in laws; limited operating history of BCF; reliance on management of BCF; requirements for additional financing; competition in North American and globally; regulatory or political change.

    There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

    Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. BCF disclaims any intention or obligation to update or revise such information, except as required by applicable law, and BCF does not assume any liability for disclosure relating to any other company mentioned herein. Reported by GlobeNewswire 8 minutes ago.

    0 0

    Airbus narrowed a sales gap against U.S. rival Boeing by finalising orders for 120 of the former Bombardier CSeries jet, but shares in Europe's top planemaker fell as doubts surfaced over a target for overall 2018 deliveries. Reported by Reuters 16 hours ago.

    0 0

    U.S. manufacturing activity slowed sharply to a two-year low in December amid a plunge in new orders and hiring at factories, suggesting the economy was probably not immune to slowing growth in China and Europe. Reported by Reuters 15 hours ago.

    0 0

    Padraig Harrington will be announced next week as the captain for Europe's 2020 Ryder Cup team, according to multiple reports. Reported by Reuters 13 hours ago.

    0 0

    Leicester City's Wilfred Ndidi named in African best XI France Football has Ndidi among the best African players in Europe. Reported by Leicester Mercury 12 hours ago.

    0 0

    Following a strong first-half rally in 2018, the copper price dropped amid a slowing Chinese economy and subdued activity in the US and Europe. Closing the year at around 25% below its June peak, concerns surrounding the strained US-China trade relationship and China’s gradual economic slowdown have been sustained into the New Year. Rhetoric from China’s leader Xi Jinping regarding the country’s commitment to a “Made in China 2025” policy, as well as little indication of a much-needed economic stimulus, have not assuaged investors and caused further steep declines in the copper price during December. However, worsening global macro conditions could potentially be offset by forecast declines in global copper production and inventories in 2019, which would positively influence prices. S&P Global predicts copper will remain at $6,100 a tonne in 2019, rising by $100 in 2020 and again in 2021 to reach $6,500 a tonne. The copper price today is sitting at just above $5,681 a tonne, or $2.577 a pound. China’s slowdown A research report from Citigroup in mid-December recognised the persistent concerns over China’s macroeconomic conditions in 2019. The report said: “Mixed China macro data, including a sharp slowdown in household consumption, call for more policy fine-tuning into 2019. “On the positive side, investment across infrastructure, manufacturing and property improved with levels of infrastructure investment surging in November following weak readings over the past few months.” Credit Suisse analysts expressed optimism in another report released in December, stating they could not rule out the Chinese government reacting to trade tensions and growth pressures by further infrastructure and construction investments. This tried-and-tested method would provide a boost for commodity demand. Slow start to 2019 The New Year began with further steep falls after data suggested China's manufacturing sector contracted in December, with global markets all closing lower on Wednesday. The ASX was down 1.6% while the Hang Seng, Shanghai Composite, FTSE, CAC and DAX all dropped between 1%-3%. Forecasts from the International Monetary Fund for world gross domestic product (GDP) growth are 3.7% for both 2018 and 2019, including slower growth for the US and China at 2.5% and 6.2%, respectively. India’s GDP is expected to grow by 7.4%. Supply-side optimism According to JPMorgan estimates, China’s demand for copper has risen by 5%-6%, with head of metals strategy at the global commodities group Natasha Kaneva saying Chinese copper demand was not as bad as people thought. The Bank of America Merrill Lynch was more cautious, noting prices were under pressure and the macro environment would remain challenging into 2019. Coupled with growing demand, forecast supply cuts from some of the world’s largest copper producers give some optimism to investors regarding the copper price over the next 12 months. Production at the Grasberg Copper Mine in Indonesia, operated by Freeport McMoran (NYSE:FCX) and Rio Tinto (LON:RIO), will fall by more than 50% next year as the mine transitions to underground operations. The transition is expected to reduce copper supply in the market by about 300,000 metric tons, or 1.5% of annual copper mine production. BHP Billiton Ltd’s Escondida Copper Mine in Chile is also expected to produce less copper this year. Sustained demand yet to show effect Speaking at the 14th Asia Copper Conference in Shanghai, a Morgan Stanley representative said many industry participants were frustrated that recent strong demand and falling exchange inventory had not resulted in a higher price. The investment bank’s speaker said supply growth to replenish falling stockpiles would be limited while disruption risk remained. “We maintain our base case forecast of a modest deficit in the copper market in 2019 of around 240,000 tons based on China’s refined demand growth. “Limited copper cathode inventory and weak supply growth make the copper market well-positioned to weather any slowdown in China’s demand, with little prospect of a significant surplus developing. “Price upside is likely to remain limited until macroeconomic sentiments turns positive.” Reported by Proactive Investors 3 hours ago.

    0 0

    The EU is looking at ways of safeguarding against cyber security risks from the purc… Reported by FT.com 3 hours ago.

    0 0

    African nation uses control of flow of people to gain leverage in Europe Reported by FT.com 4 hours ago.

    0 0

    *Press Release*
    VYZULTA Approved in Canada by Nicox's Partner
    *...............................................*

    January 4, 2019 - release at 7:30 am CET
    Sophia Antipolis, France

    *Nicox SA* (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner has received approval in Canada of VYZULTA^TM (latanoprostene bunod ophthalmic solution), 0.024%.  Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) and exclusive global licensee for VYZULTA^TM, announced the approval yesterday.  VYZULTA^TM is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

    *Michele Garufi, Chairman and Chief Executive Officer of Nicox, said:* "The Canadian approval of VYZULTA, its first approval outside the U.S., is excellent news and sets the stage for what we believe should be a strong year for Nicox.  In 2019 we anticipate for ZERVIATE a U.S. commercial launch by our partner Eyevance and potential additional licensing agreements in other geographies.  Therefore, between the revenues from VYZULTA royalties from Bausch + Lomb and the future royalty streams from ZERVIATE, we look forward to a continuous and progressive income for Nicox for the next several years."

     

    Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTA^TM as well as up to $150 million in net sales milestones linked to global sales.

     

    Bausch + Lomb's announcement (dated January 3, 2019) regarding this approval can be accessed by the following link: https://www.newswire.ca/news-releases/bausch-lomb-announces-health-canada-approval-of-vyzulta-tm-latanoprostene-bunod-ophthalmic-solution-0-024-for-the-treatment-of-glaucoma-897268417.html.

     
    *About Nicox*
    Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma.  Our portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis.  Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood).  In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIATE(TM) (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to Eyevance Pharmaceuticals.  

    Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

    For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
    *Analyst coverage*
    Bryan, Garnier & Co   Hugo Solvet    Paris, France
    Invest Securities   Martial Descoutures    Paris, France

       
     

    The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
    *Upcoming financial and business conferences*
     

    February 12, 2019  European Midcap Event   Frankfurt, Germany
    March 19-20, 2019  Oppenheimer's 29th Annual healthcare Conference  New York, U.S. 
    April 7-9, 2019  H.C. Wainwright Global Life Sciences Conference   London, UK
    *Contacts*
    *Nicox*
    Gavin Spencer,
    Executive Vice President, Chief Business Officer
    T +33 (0)4 97 24 53 00
    communications@nicox.com
    *Investors & Media*
    United States & Europe
    LifeSci Advisors, LLC
    Hans Herklots
    T +41 79 598 71 49  
    hherklots@lifesciadvisors.com  
    *Media*
    France
    LifeSci Advisors, LLC
    Sophie Baumont
    M. +33 (0)6 27 74 74 49
    sophie@lifesciadvisors.com

    * *

    * *

    * *  
    *Disclaimer*
    The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

    Risks factors which are likely to have a material effect on Nicox's business are presented in the 4^th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2017' filed with the French Autorité des Marchés Financiers (AMF) on March 19, 2018 which is available on Nicox's website (www.nicox.com).
    *Nicox S.A.*
    Drakkar 2
    Bât D, 2405 route des Dolines
    CS 10313, Sophia Antipolis
    06560 Valbonne, France
    T +33 (0)4 97 24 53 00
    F +33 (0)4 97 24 53 99

    *Attachment*

    · Press release.pdf Reported by GlobeNewswire 3 hours ago.

    0 0

    Reported by FT.com 2 hours ago.

    0 0

    Jadestone Energy Inc. Announces Readiness of Montara Asset for Production Restart *SINGAPORE / ACCESSWIRE / January 4, 2019 / *Jadestone Energy Inc. ( AIM:JSE, TSXV:JSE) ("Jadestone" or the "Company"), an independent oil and gas production company focused on the Asia Pacific region, announces the completion of works required for the restart of production from the Montara oil field, following an extensive maintenance and inspection shutdown.

    *Production restart plan*

    Work has been completed and the facilities are undergoing the final stages of pressure testing to ensure asset integrity and a safe restart of production. The oil train has been successfully leak tested and the gas train is now being tested so that both can start together, enabling immediate gas-lift and gas re-injection so as to optimise production operations, as rapidly as possible. The documentation required to lift the various improvement notices, prohibition notice and direction letter issued by NOPSEMA, are in the process of being evaluated by the regulator to allow the facility to reintroduce hydrocarbons. That close-out is anticipated within days. The conclusion of this maintenance and inspection activity will result in improved facility reliability and uptime going forwards, resulting in no major planned shutdowns until at least H2 2020.

    Jadestone and PTTEP are continuing to manage the asset under the terms of the operator and transitional services agreement whereby PTTEP, as the duty holder under the currently in-force safety case, continues to operate the Montara assets, while all critical leadership positions in the operation are now filled with Jadestone secondees. In the meantime, the regulator is reviewing Jadestone's recently submitted Montara safety case and environment plan. Upon acceptance of these, the regulator will then permit the transfer of operatorship to Jadestone.

    *Paul Blakeley, President and CEO commented:*

    "I'm pleased that the shutdown of the Montara assets has been safely concluded, which now completes all overdue inspection and maintenance items which we identified during the initial weeks after closing the transaction with PTTEP. During the shutdown, Montara personnel logged more than 9,000 hours of work, all executed without a single safety incident. This is a testament to the calibre of expertise on the asset and the leadership we have now seconded into the Montara organisation, and a key early step toward embedding the Jadestone operating philosophy and safety culture on the asset.

    "In addition to resolving the regulatory non-compliance notices, which in our view now safeguards the integrity and reliability of the Montara assets, we have worked closely with NOPSEMA, the offshore regulator, to satisfy their concerns as laid out in Direction Notice 0732, and are waiting for their final support to a full restart of production."

    *Enquiries*

    *Jadestone Energy Inc.*

    +65 6324 0359 (Singapore)

    Paul Blakeley, President and CEO

    +1 403 975 6752 (Canada)

    Dan Young, CFO

    ir@jadestone-energy.com

    Robin Martin, Investor Relations Manager



    * *



    *Stifel Nicolaus Europe Limited (Nomad, Joint Broker)*

    +44 (0) 20 7710 7600 (UK)

    Callum Stewart



    Nicholas Rhodes



    Ashton Clanfield



    * *



    *BMO Capital Markets Limited (Joint Broker)*

    +44 (0) 20 7236 1010 (UK)

    Thomas Rider



    Jeremy Low



    Thomas Hughes



    * *



    *Camarco (Public Relations Advisor)*

    + 44 (0) 203 757 4980 (UK)

    Georgia Edmonds



    jadestone@camarco.co.uk



    Billy Clegg



    James Crothers



    * *

    *About Jadestone Energy Inc.*

    Jadestone Energy Inc. is an independent oil and gas company focused on the Asia Pacific region. It has a balanced, low risk, full cycle portfolio of development, production and exploration assets in Australia, Vietnam and the Philippines.

    The Company has a 100% operated working interest in Stag, offshore Australia, and a 100% working interest in the Montara project, offshore Australia, effective January 1, 2018. Both the Stag and Montara assets include oil producing fields, with further development and exploration potential. The Company has a 100% operated working interest (subject to registration of PVEP's withdrawal) in two gas development blocks in Southwest Vietnam and is partnered with Total in the Philippines where it holds a 25% working interest in the SC56 exploration block.

    Led by an experienced management team with a track record of delivery, who were core to the successful growth of Talisman's business in Asia, the Company is pursuing an acquisition strategy focused on growth and creating value through identifying, acquiring, developing and operating assets throughout the Asia-Pacific region.

    Jadestone Energy Inc. is currently listed on the TSXV and AIM. The Company is headquartered in Singapore. For further information on Jadestone please visit http://www.jadestone-energy.com.

    *Cautionary statements*

    Certain statements in this press release are forward-looking statements and information (collectively "forward-looking statements"), within the meaning of the applicable Canadian securities legislation, as well as other applicable international securities laws. The forward-looking statements contained in this press release are forward-looking and not historical facts.

    Some of the forward-looking statements may be identified by statements that express, or involve discussions as to expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of phrases such as "will likely result", "are expected to", "will continue", "is anticipated", "is targeting", "estimated", "intend", "plan", "guidance", "objective", "projection", "aim", "goals", "target", "schedules", and "outlook"). In particular, forward-looking statements in this press release include, but are not limited to statements regarding the concurrent startup of the oil and gas trains, timing for close-out of improvement notices, prohibition notice and directive issued by NOPSEMA, timing for future maintenance shutdowns, and the future transfer of Montara operatorship.

    Because actual results or outcomes could differ materially from those expressed in any forward-looking statements, investors should not place undue reliance on any such forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes will not occur. Some of these risks, uncertainties and other factors are similar to those faced by other oil and gas companies and some are unique to Jadestone. The forward-looking information contained in this news release speaks only as of the date hereof. The Company does not assume any obligation to publicly update the information, except as may be required pursuant to applicable laws.

    This announcement contains inside information as defined in EU Regulation No. 596/2014 and is in accordance with the Company's obligations under Article 17 of that Regulation.

    *Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

    This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

    *SOURCE:* Jadestone Energy Inc.
    View source version on accesswire.com:
    https://www.accesswire.com/531860/Jadestone-Energy-Inc-Announces-Readiness-of-Montara-Asset-for-Production-Restart Reported by Accesswire 2 hours ago.

    0 0

    Gathering Quality Pharmaceutical Excipients from Around the World, PharmaExcipients China 2019 Helps the Chinese Pharmaceutical Industry Achieve Comprehensive Upgrading PharmaExcipients China 2019 to Embark on a New Journey

    SHANGHAI, Jan. 4, 2019 /PRNewswire/ -- To further give play to the role of CPhI China as an international exchange platform and serve the generic drug quality and efficacy consistency evaluation by using international, advanced ideas and technologies, *PharmaExcipients China 2019*, hosted by CCCMHPIE and UBM EMEA and co-organized by Shanghai UBM Sinoexpo, will embark on a new journey in Hall E3 of Shanghai New International Expo Centre (SNIEC) on *June 18-20*, *2019* as one of the characteristic segments of CPhI China. The exhibition will set up an international exchange and cooperation platform to link China's pharmaceutical excipients and preparation R&D; connect the pharmaceutical product R&D chain and industrial chain; propel enterprises and R&D institutions to strengthen R&D of APIs, excipients, and pharmaceutical packaging materials; promote lifecycle management, technological upgrading, and innovation of pharmaceutical products; and help enterprises continue to improve pharmaceutical excipient quality.

    Laws and regulations of many countries have placed higher requirements on pharmaceutical companies and pharmaceutical excipient suppliers in recent years, to ensure the quality and safety of pharmaceutical excipients. The relevant policies for the generic drug quality and efficacy consistency evaluation, *information registration* of APIs, excipients, and pharmaceutical packaging materials, and *related review and approval*, etc. introduced in China in recent years have made clear the primary responsibility of the preparation enterprises for the selection of pharmaceutical excipients, which means that excipient enterprises shall be fully subject to the review of preparation enterprises so as to obtain recognition thereof and achieve development and innovation. Driven by the policies, the promotion and application of the new products, new dosage forms, and new processes will bring broad markets for new pharmaceutical excipients.

    Implementation of China's new policy for related review will be a life-or-death test for preparation, pharmaceutical excipient, and pharmaceutical packaging material enterprises, and largely increase requirements for responsibilities and technology of enterprises. Some Chinese enterprises engaging in pharmaceutical excipients and pharmaceutical packaging materials are actively adjusting and reforming to improve product quality and ensure pharmaceutical product quality and safety. Additionally, more preparation enterprises have generated urgent needs for quality excipient manufacturers.PharmaExcipients China 2018

    *Gathering Chinese and overseas industry giants, and guiding structure upgrade of excipient enterprises*

    *PharmaExcipients China *has gradually become more specialized, regulated, and large-scale over the five years accompanying the excipient industry, and has become a platform for the annual gathering, exchange, and close cooperation between practitioners in the Chinese excipient industry and their peers. CPhI China attracted 60,744 visits of visitors from 120 countries and regions during the 2018 exhibition; in particular, the visits of overseas visitors showed explosive growth to reach 15,329, growing by over 50% compared to 2017, most of which were from the main countries that the Chinese excipients are exported to: the U.S., Europe, Japan, Southeast Asia, and India. Numerous exhibitors expanded their booths owing to the good exhibition results.PharmaExcipients China 2018

    As a global leading pharmaceutical excipient supplier, Shanghai Colorcon Coating Technology Co., Ltd. has cooperated with CPhI. "In the CPhI China this year, Colorcon displayed many new products such as Opadry® QX and Nutrafinish, and brought better choices to customers to help them increase film coating production efficiency and accelerate product marketing; and we also shared with customers about Colorcon's quality management system and products' regulation compliance, as well as provided solutions and relevant services for customers' products to enter the Chinese market. Furthermore, staff from Colorcon Asia-Pacific conducted in-depth exchanges with customers from different regions, to learn about customer needs and develop targeted solutions. Thanks to CPhI for providing a professional platform that draws us closer to customers!" commented Wendy Chen, the Senior Marketing Manager of Colorcon.

    PharmaExcipients China 2019 has attracted over 100 Chinese and overseas high-end excipient enterprises such as *BASF, Colorcon, Lubrizol, DuPont, Meggle, JRS, Kerry, and Avantor* to join. The exhibition is a bridge that connects the international market, expands the industrial chain, and drives the industry forward. Exhibitors have found more international partners and international well-known enterprises, enhanced their visibility, and promoted their overall value via this platform.

    *Conferences and activities in multiple forms, exhibition experiences on a deeper level*

    80+ specialized forums, conferences, and activities will be held at the exhibition for the exhibitors and visitors, wherein, *Pharmaceutical Excipients Development Forum 2019* will gather 200+ researchers and purchasers from the pharmaceutical enterprises to participate on site; IPEC's front-line experts, ICH experts, pharmacopeia experts, and authority figures from Chinese and overseas regulators, industry associations, research institutes, pharmaceutical product R&D enterprises, pharmaceutical product manufacturers, and pharmaceutical excipient enterprises will also gather there, to analyze updates of excipient guidelines of different countries, and discuss the application of new excipients in preparation development. The forum will discuss hierarchical administration, quality control technical requirements, excipient supply chain management, and the importance of quality agreements of preparation enterprises and pharmaceutical excipients, as well as explain and exchange on how to conduct related review and approval, how to change excipients for marketed preparations, and other industry hot topics, to help excipient enterprises integrate into the global industry chain.PharmaExcipients China 2018

    The *CPhI China Pharmaceutical Excipients Discovery Tour* led by industry experts will provide specialized explanations and optimize the interaction between exhibitors and visitors to embrace a new era of development by helping enterprises locate quality suppliers more quickly and more effectively, obtain the opportunities to exchange on the latest information and dynamics of the industry, achieve win-win cooperation in the industry, and boost China's generic drug consistency evaluation.

    Visit the exhibition website http://www.cphi-china.cn/excipients/en to join the industry event of pharmaceutical practitioners.

    PharmaExcipients China2019
    Concurrently with CPhI China 2019
    June 18-20, 2019 | Hall E3, SNIEC, Shanghai, China
    Organizer: UBM EMEA, CCCMHPIE
    Co-organizer: UBM Sinoexpo

    Website:
    http://www.cphi-china.cn/excipients/en

    Photo - https://photos.prnasia.com/prnh/20190102/2336264-1-a
    Photo - https://photos.prnasia.com/prnh/20190102/2336264-1-b
    Photo - https://photos.prnasia.com/prnh/20190102/2336264-1-c

    Related Links :

    http://www.cphi-china.cn/excipients/en Reported by PR Newswire Asia 2 hours ago.

    0 0

    *- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML
    **- Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual Meeting*

    SINGAPORE, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug (IND) application for ASLAN003. The company plans to evaluate ASLAN003 in the United States as part of an ongoing Phase 2 clinical trial. ASLAN003 is a potential treatment for acute myeloid leukaemia (AML), for which the FDA has previously granted Orphan Drug Designation.

    ASLAN plans to enrol patients in the United States as part of a 20-patient expansion cohort for its ongoing trial, to be conducted once an optimum dose of ASLAN003 in AML has been established. In the United States, clinical sites have been selected and we expect the clinical trial to begin in the first half of 2019. Patients will also be enrolled in the expansion cohort in Singapore and Australia, where the Phase 2a clinical trial is ongoing.

    *Dr Carl Firth, CEO of ASLAN Pharmaceuticals, commented:* “We’re excited to begin enrolling U.S. patients in our ASLAN003 Phase 2 clinical trial. We have been encouraged to see half of our evaluable patients recruited to date in our lower dose cohorts show signs of clinical activity. We expect our clinical trial activity in the United States and Asia to be supportive of potential approval in major markets and to fulfil our desire for a submission of a robust, comprehensive and compelling data package.”

    ASLAN recently presented interim data from its Phase 2a clinical trial of ASLAN003 in AML at the 2018 American Society of Hematology (ASH) Annual Meeting. As of the 16 November 2018 data cut-off, 14 patients with AML ineligible for standard treatment (including relapsed, refractory and treatment naïve) had been enrolled in the multicentre dose optimisation study to evaluate ASLAN003 monotherapy administered as a 28-day cycle. Eight patients had received at least one post-treatment assessment at the cut-off date and were evaluable for efficacy. Of the eight evaluable patients, four patients showed clinical signs of efficacy: two patients (one in the 100mg once daily [QD] cohort and one in the 200mg QD cohort) exhibited evidence of myeloid differentiation and one patient in the 100mg QD cohort developed suspected differentiation syndrome. Overall, four patients had stable disease for more than three months with ASLAN003 being well tolerated by patients.

    *Media and IR contacts*

    *Emma Thompson*
    Spurwing Communications
    Tel: +65 6340 7287
    Email: ASLAN@spurwingcomms.com* * *Robert Uhl*
    Westwicke Partners
    Tel: +1 858 356 5932
    Email: robert.uhl@westwicke.com

    *About ASLAN003*
    ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in acute myeloid leukaemia (AML). Licensed from Almirall in 2013, ASLAN has global rights for all non-topical and non- dermatological indications. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. ASLAN is conducting a Phase 2 clinical trial to develop ASLAN003 in AML and also exploring other solid tumour types where DHODH may be relevant.

    *About ASLAN Pharmaceuticals*
    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.ASLANpharma.com.

    *Forward looking statements*
    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy, the Company’s plans to develop and commercialise its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company’s product candidates. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company’s U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s prospectus dated May 8, 2018 filed with the US Securities and Exchange Commission on such date. 

    All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Reported by GlobeNewswire 2 hours ago.

    0 0

    *Elis continues its growth strategy in Denmark with the acquisition of **A-Vask A/S*

    *Saint-Cloud, January 4, 2019* - Elis, an international multi-service provider, offering textile, hygiene and facility services solutions across Europe and Latin America, is continuing its expansion strategy in its key markets and announces the closing of the acquisition of 100% of A-Vask A/S in Denmark.

    A-Vask is a family business that operates two multi-service plants in Aabenraa (Southern Denmark) and Taastrup (Copenhagen area), serving customers in Hospitality and the public sector.

    A-Vask A/S generated revenues of c. 8 million euros in 2017.

    Commenting on this announcement, *Xavier Martiré, CEO of Elis*, declared:
    "The acquisition of A-Vask A/S enables Elis to further expand its client portfolio in Hospitality and the public sector and strengthens its position in Denmark. The support of the two shareholders will facilitate the company's integration within the Group and the sharing of best practices. This acquisition is an illustration of our growth strategy and will contribute to the continuation of Elis' profitable growth."

    *Contact*

    *Nicolas Buron
    *Investor Relations Director - Phone: +33 1 75 49 98 30 - nicolas.buron@elis.com

    *Audrey Bourgeois
    *Investor Relations - Phone: +33 1 75 49 96 25 - audrey.bourgeois@elis.com

    *Attachment*

    · Elis is growing in Denmark with the acquisition of A-VASK A/S.pdf Reported by GlobeNewswire 2 hours ago.

    0 0

    Artificial Intelligence Software platform X0PA AI to acquire Nastrac Group, a global search firm

    SINGAPORE (PRWEB) January 04, 2019

    Today (Jan 2nd 2019), X0PA Ai. X0PA Ai, an Artificial Intelligence software platform for HR and recruitment have completed their acquisition of Nastrac Group, a strategic hiring and search firm.

    The acquisition combines the recruitment services expertise of Nastrac Group with X0PA’s AI products to create an innovative managed services offering to clients. The new entity aims to provide faster and better hiring decisions for clients and a completely transparent platform to candidates. This is done by using AI to match candidates to jobs and by automating parts of the hiring process.

    All current clients from Nastrac Group will be taken over into X0PA Managed Services, where all of the current services provided will continue. Along with the acquisition, in early the early stages of this year (2019) X0PA Ai will open a new office in Helsinki, Finland. This office is designed to penetrate the European market, opening the client base up to another region. The current CEO of Nastrac Group Farida Charania will take over the new role of Head of Europe with immediate effect and will be based out of Helsinki which is identified as the European headquarter of X0PA.

    “This acquisition helps us to offer creative solutions to our clients both on the product as well as services and help companies reduce their cost and time of hiring by 87% and dramatically improve the quality of hire,” says Nina Alag Suri, Founder and CEO X0PA AI.

    “Nastrac’s 20 years of experience and global presence, domain knowledge and insights are key to our data modelling and algorithms. I am delighted with this acquisition, it will further enable us to create innovative AI solutions for our platform,” said Jussi Keppo Co- Founder and Head of Data Science at X0PA AI.

    X0PA AI will be acquiring 100% of Nastrac Group. The current shareholdings will be swapped to shares in X0PA.

    About X0PA AI- http://www.x0pa.com

    X0PA is an artificial intelligence platform that helps talent management. X0PA’s AI-powered recruiter Roboroy saves you time, money, resources and above all predicts the best-fit candidates. For existing employees, predicting attrition and performance identifies red flags before the attrition problem becomes a real one. RoboRoy helps companies reduce their time to hire by 87% and reduce the cost to hire by 50%. Reported by PRWeb 1 hour ago.

    0 0

    Private insurance segment of geriatric care services market is projected to expand at 9.2% CAGR over the forecast time period as various private insurance companies help to avoid the Medicare levy surcharge and makes sure that public hospital waiting list is not very long will propel the industry growth.

    Sellbyville, Delaware, Jan. 04, 2019 (GLOBE NEWSWIRE) --Germany dominated the Europe geriatric care services market and was valued around USD 73,809.2 million in the year 2017. Increasing demand of attractive and cost-saving insurance plans for the elderly population is fueling the market growth in Germany. Additionally, increase in healthcare expenditure for the elderly people in Germany has led to growth in effective reimbursement policies, hence driving the business growth in the country.

    Global Geriatric Care Services Market will surpass USD 1,490.5 billion by 2024; according to a new research study published by Global Market Insights, Inc. Rising geriatric population base coupled with growing number of chronic diseases and increasing number of long-term care services is driving the geriatric care services market size over the forecast timeframe. As per the UN estimates, elderly population was over 800 million in 2012, projected to surpass 2,000 billion by 2050, hence propelling the global market growth.

    Additionally, the increase in elderly population coupled with presence of various home care services, day care facilities and geriatric care establishments are likely to further enhance the geriatric care services market growth. Moreover, growing geriatric people who are susceptible to several medical complications such as neurological, respiratory, orthopedic and cardiovascular diseases coupled with increase in the advancement of technology such as the development of specialty robots skilled for assisting old people in carrying out day-to-day operations is anticipated to drive the geriatric care services market. Growing elderly population living on their own and increasing demand for effective geriatric care services will fuel business growth over the forecast period.

    *Request for a sample of this research report @ *https://www.gminsights.com/request-sample/detail/433

    High cost associated with geriatric care services will be a market impeding factor. In addition, lack of geriatric services in developing countries will decrease the demand, thus hindering the market growth.

    Institutional care market was valued around USD 545,328.5 million in the year 2017. Presence of various nursing homes, hospitals, assisted living centers, and independent senior living centers for medical care of elderly patients is boosting the business growth in the forthcoming years.

    Browse key industry insights spread across 250 pages with 342 market data tables & 9 figures & charts from the report, *“Geriatric Care Services Market” i*n detail along with the table of contents:

    https://www.gminsights.com/industry-analysis/geriatric-care-services-market-report

    Home care market is estimated to grow at a CAGR of 9.2% over the projection period. Several advantages offered by home care services such as lower risk of rehospitalization, greater convenience, better quality of life, and lower medical bills will boost the care service demand. Additionally, some of the best home care centers offer enrichment programs for elderly patients that are tailored to each person, accordingly, hence propelling the industry growth in the forthcoming years.

    Public service provider in geriatric care services market was valued around USD 616,025.4 million in the year 2017. The growing demand to cover eligible elderly population from bearing the direct burden of most health care expenditure is driving the market growth. Furthermore, in western countries like U.S., Germany, and France, governments are under increasing pressure to ensure that their citizens have access to superior healthcare services at a reasonable cost, that will in turn accentuate the market demand for public service providers.

    The age category of 65-70 years in geriatric care services market is projected to grow at a considerable CAGR of 9.9% over the forecast timeframe. Increasing sedentary lifestyle, alcohol consumption and smoking is making way for an array of chronic diseases, fueling the market growth in the forthcoming years. In addition, people in the age category of 65-70 years are extremely prone to infectious diseases as well as suffer from serious orthopedic issues, that will boost the market growth.

    U.S. geriatric care services market is estimated to grow at robust CAGR of 7.6% during the projection period. Increase in number of geriatric populations affected with chronic diseases, recent technological advancements in geriatric care services and high healthcare expenditure in U.S. will result in largest market share in the global market.

    Some of the leading players in the geriatric care services market include Brookdale Senior Living Inc., Extendicare Inc., Gentiva Health services, Inc., Kindred Healthcare Inc., Senior Care Centers of America, Sunrise Senior Living Inc., Genesis Healthcare Corp., Home Instead Senior Care Inc., and GGNSC Holdings, LLC. These companies opt for strategic decisions such as mergers, acquisitions, and partnerships in order to increase their efficiency and sustain in the market.

    *Make an inquiry for purchasing this report @* https://www.gminsights.com/inquiry-before-buying/433

    *Browse Related Reports:*

    · *Blood Gas and Electrolyte Analyzers Market Size Forecast 2018 – 2024*

    The Blood Gas and Electrolyte Analyzers Market exceeded USD 3.2 billion in 2017 and is expected to witness 6.8% CAGR from 2018 to 2024 owing to surge in adoption of blood gas and electrolyte analyzers in emergency wards.

    https://www.gminsights.com/industry-analysis/blood-gas-and-electrolyte-analyzers-market-report

    · *Carcinoembryonic Antigen Market Size Outlook 2018 – 2024*

    The Carcinoembryonic Antigen Market surpassed USD 1.9 billion in 2017 and is expected to witness more than 6.7% CAGR from 2018 to 2024 owing to increasing consumption of alcohol, processed food, along with sedentary lifestyles.      
    https://www.gminsights.com/industry-analysis/carcinoembryonic-antigen-cea-market-report

    *About Global Market Insights*

    Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

    CONTACT: Contact Us:
    Arun Hegde
    Corporate Sales, USA
    Global Market Insights, Inc.
    Phone: 1-302-846-7766
    Toll Free: 1-888-689-0688
    Email: sales@gminsights.com
    Web: https://www.gminsights.com
    Blog: http://allnewsmyway.com/ Reported by GlobeNewswire 1 hour ago.

    0 0

    *Quanta Appoints Dr. Paul Komenda as New Chief Medical Officer*

    *Alcester, Warwickshire, UK, 4 January 2019:* Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company has appointed Dr. Paul Komenda as Chief Medical Officer.

    Dr. Komenda, Associate Professor of Medicine at the University of Manitoba, is a fellow of the American Society of Nephrology and has extensive clinical and academic experience. Dr. Komenda previously served on the Scientific Advisory Board of NxStage Medical. He gained his medical qualification in 2001 from the University of Manitoba and is a board certified Nephrologist. Dr. Komenda studied health economics at the University of Calgary, holds a Masters in Health Administration and is also the Medical Director of the Home Dialysis Program at the Seven Oaks General Hospital in Manitoba.

    Dr. Komenda has over 130 published peer reviewed articles in health services research and clinical nephrology and, with a specialist knowledge and interest in the field of home dialysis and health economics, Dr. Komenda is highly regarded as an expert in his field.

    *John E. Milad, Chief Executive Officer of Quanta, commented on the appointment:* “We are excited to have Dr. Komenda join Quanta as our Chief Medical Officer. He brings a wealth of knowledge and expertise as a respected global thought-leader with extensive clinical experience in home dialysis. He will be invaluable to Quanta’s future success as we prepare to launch our innovative personal haemodialysis system, SC+, later this year in Europe.”

    *Dr. Komenda, Chief Medical Officer of Quanta, commented: *“I have followed Quanta with interest over the past few years and have been inspired by the innovative work it is doing in the field of haemodialysis. SC+ is a unique system which offers patients flexibility, convenience and control over their choice of treatment and I am excited to work with the team to bring this technology to market to improve the quality of life of dialysis patients.”

    *-ENDS-*

    *For more information about Quanta, please contact:*

    * *

    *Quanta*

    John E. Milad,
    Chief Executive Officer

       T: +44 (0)1789 400043

    E: enquiries@quantadt.com
    *Consilium Strategic Communications*

    Mary-Jane Elliott / Matthew Neal / Lindsey Neville

      T: +44 (0)203 709 5708

    E: quanta@consilium-comms.com

    *About SC+ *

    SC+ is a unique small, simple and powerful haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users across a wide range of settings.

    *About Quanta *

    Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta’s lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba Life Sciences, b-to-v Partners, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.

    For more information, please visit: www.quantadt.com. Reported by GlobeNewswire 1 hour ago.

    0 0

    Boca Juniors teenage sensation Augustin Almendra has caught the eye of several of Europe’s top teams thanks to his flying form with the Argentine heavyweights. The 18-year-old has previously been linked with the likes of Barcelona and Valencia but the Italian media report that Serie A hotshots Napoli have emerged as frontrunners for his signature. […]

    The post Napoli launch attack on Augustin Almendra appeared first on Soccer News. Reported by SoccerNews.com 7 minutes ago.

    0 0

    Tesla Model 3-rivalling electric saloon will be unveiled in full in the next few weeks

    Volvo's electric performance brand Polestar has released a teaser image previewing the design of its upcoming Polestar 2 four-door coupé ahead of its release in the second half of this year. 

    The Tesla Model 3 rival will follow Polestar's first model, the hybrid-powered Polestar 1, which will go on sale in Europe in Summer 2019. 

    Details are scarce, but the company refers to the model's body style as that of a four-door "fastback", and states that it will be the first vehicle to feature Google's new human-machine interface technology and the in-car version of Google Assistant. 

    The company says the new model will "be sold in the Tesla Model 3 price range", suggesting a likely starting price of around £50,000. Customers will purchase the Polestar 2 on a subscription basis, set to take the form of "a slightly more premium version" of Volvo's own Care by Volvo scheme. 

    The company says a full reveal will take place in the coming weeks, but claims the Polestar 2 will produce up to 400bhp and offer a claimed range of roughly 300 miles. 

    Speaking to Autocar at the Goodwood Festival of Speed in 2018, Polestar COO Jonathan Goodman confirmed some details of the new model. 

    Talking about the range of the entry-level model, he said: "That will represent the lower ‘bookend’ of our showroom range and, for now, it should give us as much access to the volume end of the EV market as we need." 

    The Polestar 2 is understood to closely relate to Volvo's 40.2 concept shown early in 2017, alongside the 40.1 concept which has since been revealed in production form as the XC40 compact SUV.

    Goodman also warned that any established manufacturer that launches an EV sub-brand built on alternative design over the next few years might be making a big mistake, given the pace at which the market for EVs is set to develop.

    “The global electric car market was worth four million units in 2017,” explained Goodman, “but it’s quite widely expected to be worth 29m units by 2025. EV owners will come from all walks of life. So it’s a mistake to assume that, because the cars are electric, you have to make them quirky or futuristic.

    "Other brands may be doing that, but if we’re looking at a market worth 30m cars within seven years, it isn’t going to be niche, it’s going to be mainstream. So you just design a great-looking car – not one with a big blue flash down the side.”

    In contrast to the cultish following that rival brand Tesla has attracted, Goodman also wants Polestar to have an inclusive attitude towards its customers.“I think it’s very dangerous for brands like ours to sit here and ask ‘what’s our type of customer?'", he went on.

    “Electric cars will be just as appealing to young executives as they are to retirees. It’s a new market, and purchase intentions will vary. So we’ve got to be a welcoming brand that’s not geeky, cliquey or judgmental.” 

    *Read more*

    *Tesla Model 3 review*

    *Polestar 1 prototypes enter production*

    *New electric cars 2019/2020: What’s coming and when?​* Reported by Autocar 6 hours ago.

    0 0

    Callum Hudson-Odoi has made his name as one of Chelsea’s finest young talents, so much so that Maurizio Sarri said he could become one of Europe’s best players. Unfortunately, the 18-year-old is being eluded of any first team chances by his boss, with the Italian insisting he has to be “patient” to get game time. […] Reported by talkSPORT 5 hours ago.

older | 1 | .... | 1612 | 1613 | (Page 1614) | 1615 | 1616 | .... | 1652 | newer